[6-K] Novo-Nordisk A/S Current Report (Foreign Issuer)
Novo Nordisk (NVO) filed a Form 6-K disclosing insider transactions under EU Market Abuse Reg. 19. Executive Vice President Martin Holst Lange sold company B-shares on 7 Aug 2025 in two separate trades:
- 74 shares at DKK 316.75 (total DKK 23,439.50)
- 13,950 shares at DKK 316.48 (total DKK 4,414,898.43)
The combined sale amounts to 14,024 shares valued at DKK 4.44 million (≈ USD 0.65 million). One trade was executed through Citigroup Global Markets Europe AG; the larger block was carried out outside a trading venue. No purchases, option exercises, or other corporate events were reported, and no financial performance data accompanied the filing. The disclosure fulfills statutory reporting obligations but does not indicate any change in strategy, guidance, or fundamentals.
Novo Nordisk (NVO) ha presentato un modulo 6-K comunicando operazioni di insider secondo il Regolamento UE sul Market Abuse, articolo 19. Il Vice Presidente Esecutivo Martin Holst Lange ha venduto azioni B della società il 7 agosto 2025 in due transazioni separate:
- 74 azioni a DKK 316,75 (totale DKK 23.439,50)
- 13.950 azioni a DKK 316,48 (totale DKK 4.414.898,43)
La vendita complessiva ammonta a 14.024 azioni per un valore di 4,44 milioni di corone danesi (circa 0,65 milioni di dollari USA). Una delle operazioni è stata eseguita tramite Citigroup Global Markets Europe AG; il blocco più grande è stato effettuato fuori da una sede di negoziazione. Non sono stati segnalati acquisti, esercizi di opzioni o altri eventi societari, né dati finanziari sono stati allegati al documento. Questa comunicazione soddisfa gli obblighi di legge ma non implica alcuna modifica di strategia, previsioni o dati fondamentali.
Nuevo Nordisk (NVO) presentó un formulario 6-K divulgando transacciones de insiders según el Reglamento Europeo de Abuso de Mercado, artículo 19. El Vicepresidente Ejecutivo Martin Holst Lange vendió acciones clase B de la empresa el 7 de agosto de 2025 en dos operaciones separadas:
- 74 acciones a DKK 316,75 (total DKK 23,439.50)
- 13,950 acciones a DKK 316,48 (total DKK 4,414,898.43)
La venta combinada suma 14,024 acciones valoradas en 4.44 millones de coronas danesas (aproximadamente 0.65 millones de dólares). Una operación se realizó a través de Citigroup Global Markets Europe AG; el bloque mayor se ejecutó fuera de un mercado regulado. No se reportaron compras, ejercicios de opciones u otros eventos corporativos, ni se adjuntaron datos financieros al informe. La divulgación cumple con las obligaciones legales pero no indica cambios en la estrategia, previsiones o fundamentos.
노보 노디스크(NVO)는 EU 시장 남용 규정 19조에 따른 내부자 거래를 공개하는 6-K 양식을 제출했습니다. 최고 부사장 마틴 홀스트 랑게는 2025년 8월 7일 회사 B주식을 두 차례에 걸쳐 매도했습니다:
- 74주를 DKK 316.75에 매도 (총 DKK 23,439.50)
- 13,950주를 DKK 316.48에 매도 (총 DKK 4,414,898.43)
총 매도량은 14,024주이며, 가치는 444만 DKK(약 65만 달러)입니다. 한 거래는 Citigroup Global Markets Europe AG를 통해 이루어졌고, 더 큰 규모의 거래는 거래소 외부에서 실행되었습니다. 매수, 옵션 행사 또는 기타 기업 이벤트는 보고되지 않았으며, 재무 성과 데이터도 제출되지 않았습니다. 이 공개는 법적 보고 의무를 충족시키기 위한 것이며, 전략, 전망 또는 기본 사항의 변화를 나타내지 않습니다.
Novo Nordisk (NVO) a déposé un formulaire 6-K divulguant des transactions d'initiés conformément au règlement européen sur les abus de marché, article 19. Le vice-président exécutif Martin Holst Lange a vendu des actions de classe B de la société le 7 août 2025 lors de deux opérations distinctes :
- 74 actions à 316,75 DKK (total 23 439,50 DKK)
- 13 950 actions à 316,48 DKK (total 4 414 898,43 DKK)
La vente totale s'élève à 14 024 actions évaluées à 4,44 millions de DKK (environ 0,65 million de dollars). Une transaction a été réalisée via Citigroup Global Markets Europe AG ; le bloc plus important a été effectué en dehors d'un lieu de négociation. Aucun achat, exercice d'option ou autre événement d'entreprise n'a été signalé, et aucun résultat financier n'a été joint au dépôt. Cette divulgation satisfait aux obligations légales de déclaration mais n'indique aucun changement de stratégie, de prévisions ou de fondamentaux.
Novo Nordisk (NVO) reichte ein Formular 6-K ein, das Insider-Transaktionen gemäß der EU-Marktmissbrauchsverordnung Artikel 19 offenlegt. Executive Vice President Martin Holst Lange verkaufte am 7. August 2025 B-Aktien des Unternehmens in zwei separaten Transaktionen:
- 74 Aktien zu DKK 316,75 (insgesamt DKK 23.439,50)
- 13.950 Aktien zu DKK 316,48 (insgesamt DKK 4.414.898,43)
Der Gesamtverkauf beläuft sich auf 14.024 Aktien im Wert von 4,44 Millionen DKK (≈ 0,65 Millionen USD). Eine Transaktion wurde über Citigroup Global Markets Europe AG ausgeführt; der größere Block erfolgte außerhalb eines Handelsplatzes. Es wurden keine Käufe, Optionsausübungen oder andere Unternehmensereignisse gemeldet, und dem Bericht lagen keine Finanzdaten bei. Die Offenlegung erfüllt die gesetzlichen Meldepflichten, weist jedoch nicht auf eine Änderung der Strategie, Prognosen oder Fundamentaldaten hin.
- None.
- Executive share sale could be perceived negatively by some investors despite its immaterial size relative to Novo Nordisk’s market capitalisation.
Insights
TL;DR: EVP sold ~14k shares (DKK 4.4 m); immaterial to valuation but may signal modest profit-taking.
The transaction equals roughly 0.0002 % of Novo Nordisk’s ~5.0 bn outstanding shares and less than one day’s average NOK volume, suggesting negligible dilution or liquidity impact. Insider sales can trigger sentiment concerns, yet the small size and absence of multiple executives reduce interpretive weight. No new financials, pipeline updates, or strategic moves were released; therefore, the filing is largely procedural. I view the impact as neutral with a slight negative tilt driven solely by optics.
TL;DR: Routine MAR 19 disclosure; governance practices remain strong.
Novo Nordisk continues timely reporting of PDMR transactions, reinforcing transparency. The power-of-attorney arrangement centralises disclosure and limits compliance risk. Transaction outside a regulated venue is permitted but warrants investor attention to ensure best execution. No pattern of aggressive insider selling is evident. Overall governance posture is unaffected.
Novo Nordisk (NVO) ha presentato un modulo 6-K comunicando operazioni di insider secondo il Regolamento UE sul Market Abuse, articolo 19. Il Vice Presidente Esecutivo Martin Holst Lange ha venduto azioni B della società il 7 agosto 2025 in due transazioni separate:
- 74 azioni a DKK 316,75 (totale DKK 23.439,50)
- 13.950 azioni a DKK 316,48 (totale DKK 4.414.898,43)
La vendita complessiva ammonta a 14.024 azioni per un valore di 4,44 milioni di corone danesi (circa 0,65 milioni di dollari USA). Una delle operazioni è stata eseguita tramite Citigroup Global Markets Europe AG; il blocco più grande è stato effettuato fuori da una sede di negoziazione. Non sono stati segnalati acquisti, esercizi di opzioni o altri eventi societari, né dati finanziari sono stati allegati al documento. Questa comunicazione soddisfa gli obblighi di legge ma non implica alcuna modifica di strategia, previsioni o dati fondamentali.
Nuevo Nordisk (NVO) presentó un formulario 6-K divulgando transacciones de insiders según el Reglamento Europeo de Abuso de Mercado, artículo 19. El Vicepresidente Ejecutivo Martin Holst Lange vendió acciones clase B de la empresa el 7 de agosto de 2025 en dos operaciones separadas:
- 74 acciones a DKK 316,75 (total DKK 23,439.50)
- 13,950 acciones a DKK 316,48 (total DKK 4,414,898.43)
La venta combinada suma 14,024 acciones valoradas en 4.44 millones de coronas danesas (aproximadamente 0.65 millones de dólares). Una operación se realizó a través de Citigroup Global Markets Europe AG; el bloque mayor se ejecutó fuera de un mercado regulado. No se reportaron compras, ejercicios de opciones u otros eventos corporativos, ni se adjuntaron datos financieros al informe. La divulgación cumple con las obligaciones legales pero no indica cambios en la estrategia, previsiones o fundamentos.
노보 노디스크(NVO)는 EU 시장 남용 규정 19조에 따른 내부자 거래를 공개하는 6-K 양식을 제출했습니다. 최고 부사장 마틴 홀스트 랑게는 2025년 8월 7일 회사 B주식을 두 차례에 걸쳐 매도했습니다:
- 74주를 DKK 316.75에 매도 (총 DKK 23,439.50)
- 13,950주를 DKK 316.48에 매도 (총 DKK 4,414,898.43)
총 매도량은 14,024주이며, 가치는 444만 DKK(약 65만 달러)입니다. 한 거래는 Citigroup Global Markets Europe AG를 통해 이루어졌고, 더 큰 규모의 거래는 거래소 외부에서 실행되었습니다. 매수, 옵션 행사 또는 기타 기업 이벤트는 보고되지 않았으며, 재무 성과 데이터도 제출되지 않았습니다. 이 공개는 법적 보고 의무를 충족시키기 위한 것이며, 전략, 전망 또는 기본 사항의 변화를 나타내지 않습니다.
Novo Nordisk (NVO) a déposé un formulaire 6-K divulguant des transactions d'initiés conformément au règlement européen sur les abus de marché, article 19. Le vice-président exécutif Martin Holst Lange a vendu des actions de classe B de la société le 7 août 2025 lors de deux opérations distinctes :
- 74 actions à 316,75 DKK (total 23 439,50 DKK)
- 13 950 actions à 316,48 DKK (total 4 414 898,43 DKK)
La vente totale s'élève à 14 024 actions évaluées à 4,44 millions de DKK (environ 0,65 million de dollars). Une transaction a été réalisée via Citigroup Global Markets Europe AG ; le bloc plus important a été effectué en dehors d'un lieu de négociation. Aucun achat, exercice d'option ou autre événement d'entreprise n'a été signalé, et aucun résultat financier n'a été joint au dépôt. Cette divulgation satisfait aux obligations légales de déclaration mais n'indique aucun changement de stratégie, de prévisions ou de fondamentaux.
Novo Nordisk (NVO) reichte ein Formular 6-K ein, das Insider-Transaktionen gemäß der EU-Marktmissbrauchsverordnung Artikel 19 offenlegt. Executive Vice President Martin Holst Lange verkaufte am 7. August 2025 B-Aktien des Unternehmens in zwei separaten Transaktionen:
- 74 Aktien zu DKK 316,75 (insgesamt DKK 23.439,50)
- 13.950 Aktien zu DKK 316,48 (insgesamt DKK 4.414.898,43)
Der Gesamtverkauf beläuft sich auf 14.024 Aktien im Wert von 4,44 Millionen DKK (≈ 0,65 Millionen USD). Eine Transaktion wurde über Citigroup Global Markets Europe AG ausgeführt; der größere Block erfolgte außerhalb eines Handelsplatzes. Es wurden keine Käufe, Optionsausübungen oder andere Unternehmensereignisse gemeldet, und dem Bericht lagen keine Finanzdaten bei. Die Offenlegung erfüllt die gesetzlichen Meldepflichten, weist jedoch nicht auf eine Änderung der Strategie, Prognosen oder Fundamentaldaten hin.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 7, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Page 2 of 4
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) |
Price(s) and volume(s) |
||||
| Price(s) | Volume(s) | ||||
| DKK 316.75 | 74 | ||||
| d) |
Aggregated information
|
74 shares DKK 23,439.50 |
|||
| e) | Date of the transaction | 2025-08-07 | |||
| f) | Place of the transaction | (CGET) CITIGROUP GLOBAL MARKETS EUROPE AG - EMEA TRADING |
|||
Page 3 of 4
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) |
Price(s) and volume(s) |
||||
| Price(s) | Volume(s) | ||||
| DKK 316.48 | 13,950 | ||||
| d) |
Aggregated information
|
13,950 shares DKK 4,414,898.43 |
|||
| e) | Date of the transaction | 2025-08-07 | |||
| f) | Place of the transaction | Outside a trading venue | |||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 4 of 4
Contacts for further information
| Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 3444 2613 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 21/ 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: August 7, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
How many Novo Nordisk shares did EVP Martin Holst Lange sell?
What was the total value of the insider sale disclosed by NVO?
At what prices were the Novo Nordisk shares sold?
Does the Form 6-K include any earnings or guidance updates?
Where were the transactions executed?
Is this insider sale material to Novo Nordisk investors?
